Corcept targets $3B-$5B in Cushing’s revenue in 2030 as it awaits December 17 relacorilant FDA decision

• "Our revenue in the third quarter of 2026 was $340.5 million" and "we are reiterating our 2026 revenue guidance of $1.1 billion to $1.2 billion" (CFO & Treasurer Atabak Mokari).

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.